Assessing West Pharmaceutical Services (WST) Valuation After Earnings Beat And Upbeat 2026 GLP 1 Guidance

2026-03-12 02:47:06

West Pharmaceutical Services (WST) reported strong Q4 2025 earnings and provided positive 2026 guidance, emphasizing its GLP-1 exposure and plans for shareholder returns. Despite recent share price pressure, the company is seen as potentially undervalued with a fair value of $338.57, driven by expected revenue growth, margin improvement from new automated delivery devices, and GLP-1 market opportunities. However, its current P/E of 36.2x is higher than industry averages, suggesting a full valuation that could limit upside if growth expectations are not met.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes